%0 Journal Article
%T Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
%A Chengfang Lyu
%A Hongbin Meng
%A Hongjuan Yu
%A Jie Liu
%A Jin Zhou
%A Limin Li
%A Mengyuan Xu
%A Mingwen Zhang
%A Xiaoqian Zhang
%A Xiaoxia Li
%A Yueyue Fu
%J Archive of "OncoTargets and therapy".
%D 2018
%R 10.2147/OTT.S161919
%K AML
%K refractory diseases
%K relapsed diseases
%K decitabine
%K chemotherapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190628/